Newer Lung Cancer Drug Alone Beats Older Combination Therapy in Real-World Study
A large real-world study in China found that third-generation EGFR inhibitor monotherapy extended progression-free survival in advanced EGFR-mutant lung cancer ...
A large real-world study in China found that third-generation EGFR inhibitor monotherapy extended progression-free survival in advanced EGFR-mutant lung cancer ...
A province-wide cohort study of 7,474 treatment-naïve adults in Shandong, China finds INSTI-based initial HIV therapy outperforms NNRTI-based regimens on ...
A 52-week Japanese observational study found that tildrakizumab sustained meaningful disease control in real-world psoriasis patients, with 60 percent achieving ...
A multicenter Italian study and an accompanying commentary provide real-world evidence that early lumacaftor/ivacaftor therapy improves CFTR function biomarkers and ...
A multicenter Brazilian study finds intravenous esketamine produced faster antidepressant response in treatment-resistant depression, while a longer subcutaneous protocol achieved ...
A Taiwanese post-marketing surveillance study finds that nearly half of patients who failed to reach the approved 3.0 mg liraglutide ...
A large real-world study of Medicare beneficiaries found mepolizumab matched dupilumab for preventing asthma hospitalizations and significantly reduced exacerbation rates, ...
A nationwide analysis of 8,104 Hungarian patients treated from 2013 to 2022 shows median survival of just 9.3 months with ...
A study of nearly 74,000 patients across 53 healthcare organisations found that diabetes mellitus was not associated with an increased ...
A real-world study from Abu Dhabi found that pairing two advanced therapies with different mechanisms achieved combined clinical and biochemical ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine